The purpose is to determine whether long‑term use of Admilparant is safe and does not lead to serious side effects.

Participants will take one tablet each day for several years while doctors perform regular check‑ups. At each visit routine blood work, a quick heart test called an ECG that records the heart’s electrical activity, and measurements of blood pressure and heart rate are done. The study records any side effects, changes in test results, or reasons to stop the medication, and follows each person from the start until the study ends.

The purpose of the study is to determine whether nemolizumab can safely reduce skin thickness and improve overall health in adults with Systemic sclerosis while identifying the most effective dose.

Adults who join the trial will receive a series of subcutaneous injections over a 52‑week main treatment period, after which they may continue receiving the medication for an additional 156 weeks if they choose to stay in the study. Throughout the study, participants will have regular clinic visits where doctors will assess skin thickness using a scoring system called the modified Rodnan Skin Score, measure lung capacity with a test known as forced vital capacity, and evaluate overall response using the Composite Response Index in Systemic Sclerosis. Safety will be monitored by checking vital signs, laboratory tests, and any side effects that arise.

The purpose of the study is to assess the safety and tolerability of the different treatment regimens. After an initial screening visit, participants will begin a series of injection visits that continue for several months, with regular clinic appointments to check health status, record any side effects, and perform routine laboratory tests. The study follows participants for up to about four years to observe long‑term outcomes.

Safety monitoring includes tracking any new medical problems that arise during the trial. In addition, doctors will use a camera procedure called endoscopic examination to look inside the colon and evaluate improvement of the disease after about one year. This information, together with the safety data, helps determine whether the antibodies are well tolerated and potentially beneficial for people with ulcerative colitis.

The purpose of the trial is to determine whether the combination of these therapies can keep the cancer from returning for a longer time compared with placebo.

After surgery, participants are randomly assigned to receive either the active combination of medicines or the placebo, with injections given at regular intervals over several months. Throughout the study, participants attend follow‑up visits where doctors check for any side effects, monitor overall health, and perform routine scans or tests to see if the cancer comes back.

Participants receive the medication by an intravenous infusion, meaning it is given through a vein, with the amount of drug increased gradually in the early part of the study to find a safe level, followed by a larger group receiving that level to see early signs of effectiveness. Throughout the study, regular blood tests are done to measure PSA (a protein that can indicate prostate cancer activity), check organ function, and look for any side effects. Imaging scans are also performed at set intervals to see if tumors shrink or stop growing. The study follows each participant for several months, recording any adverse events, changes in laboratory results, and overall health status.

The primary aim of the trial is to determine whether the new combination improves the time patients live without their disease getting worse and, for a portion of the study, also extends overall survival compared with standard care.

Participants are randomly assigned to receive either the experimental medicines or the usual therapy, with treatment given in repeated cycles of intravenous infusions and oral tablets over several months. Throughout the study, doctors monitor tumor size using imaging scans evaluated by the criteria called RECIST 1.1, record how long the disease stays stable (progression free survival), note the length of life from start of treatment (overall survival), and assess how many patients experience tumor shrinkage (objective response rate). Safety is evaluated by tracking side effects, vital signs, laboratory tests and heart rhythm recordings.

Participants in the study will receive Nemtabrutinib in the form of a tablet taken by mouth. The study is divided into two parts. In the first part, the focus is on understanding the safety and how well the body can tolerate Nemtabrutinib. In the second part, the study will look at how well the medication works in treating the different types of blood cancers mentioned. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Nemtabrutinib.

The study will take place over a period of time, with participants being monitored for any side effects and the effectiveness of the treatment. The goal is to gather information that could help improve treatment options for people with these types of blood cancers. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to collect valuable data on the medication’s impact.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

Participants are assigned at random to receive either ASP3082 plus chemotherapy or the placebo plus chemotherapy. The study drug is delivered by intravenous infusion, a process where the medication is slowly introduced into a vein. Treatment cycles are repeated every few weeks, and patients are monitored over several months for changes in tumor size, side effects, and overall health status before the study concludes.